昌紅科技(300151.SZ):德盛投資擬認購PharmaSens新發行記名股份3.3569萬股
格隆匯12月7日丨昌紅科技(300151.SZ)公佈,公司全資子公司德盛投資有限公司(簡稱“德盛投資”)擬認購PharmaSens AG(簡稱“PharmaSens”)新發行記名股份33,569股,發行價格100瑞士法郎/股,預計佔其本次發行後總股本比例的5%股權,交易金額3,356,900瑞士法郎(具體金額以實際匯出當天匯率計算為準)。本次投資認購資金來源於德盛投資自有資金。
公司本次投資是基於經營發展和業務發展規劃戰略佈局的需要,擬投資PharmaSens AG的主營業務是貼敷式胰島素泵的研發與製造,有利於公司醫療器械及耗材領域在實時血糖檢測、胰島素治療等細分賽道的業務拓展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.